This study investigates the generation of monocyte-derived dendritic cells of lymphoma patient’s peripheral blood mononuclear cells then; these cells were used as vaccine. The results conclude that the use of dendritic cell probably is one of the suitable noninvasive treatments for lymphoma patients that they have not response to chemical drugs.
8 patients with Diffuse large B cell Lymphoma ages 17-59 years old with mean age of 45.37.
• Peripheral blood mononuclear cells were isolated from heparinized blood by centrifugation on a Ficoll Histipaque 1.007
• Cell from interphases were collected and washed three times with RPMI-1640 medium
• CD14+ monocytes (5×105) were cultured in RPMI-1640 medium supplemented with 10% patient serum, 100 u/mL penicillin, 10 ug/mL streptomycin for 5 days with different combinations of human recombinant human cytokines: 10 ug/mL human IL-4 and 10 ug/mL human GMC-SF to generate immature DCs
• Immature DC were further incubated with 10 ug/mL TNF-a and 10 ug/mL antigen suspension for additional 48 hours before harvest.
Antigen-primed DCs were administered Subcutaneously (SC) close to inguinal lymph nodes. 3-10×106 DC were injected per vaccine.
Before vaccination the mean SD of serum LDH was 530.62 + 140.65 and after vaccination it was 459 +109.45 that was statistically significant.
CD4+ SD – CD8+ SD
Before vaccination 19.64+11.75.- 6.16 + 3.33
After vaccination 25.71+16.35 – 11.81 + 3.21
In this study, tumor sized in 8 patients decreased after Dendritic cell vaccine. This shows that LDH as a tumor marker decreased after 7 days of vaccination. The results shows that this method is a beneficial method for resistant patient to anticancer drugs. It is concluded that antigen treated DCs vaccine can improved lifestyle of patients with lymphoma.